Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

INO

Ранг среди акций #23526
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research,... Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Цена акции
$1.02
Рыночная капитализация
$70.13M
Изменение (1 день)
2.51%
Изменение (1 год)
-87.38%
Страна
US
Торговля Inovio Pharmaceuticals, Inc. (INO)

Категория

Healthcare
Операционная маржа для Inovio Pharmaceuticals, Inc. (INO)
Операционная маржа на 2026 TTM: 0.00%
Согласно последним финансовым отчетам и цене акций Inovio Pharmaceuticals, Inc., текущая операционная маржа (TTM) составляет 0.00%. В конце 2026 она составила 0.00%.
История операционной маржи Inovio Pharmaceuticals, Inc. с 2026 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
Недостаточно данных для указанных дат.
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.